Therapeutic approaches to muscular dystrophy

Human Molecular Genetics

Volumn 20, Issue , 2011, Pages

  Goyenvalle, Aurélie ^a   Seto, Jane T ^b   Davies, Kay E ^a   Chamberlain, Jeffrey ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; UTROPHIN; VIRUS VECTOR;

ANTISENSE THERAPY; ARTICLE; CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE REPLACEMENT THERAPY; GENE THERAPY; HUMAN; MOLECULAR MECHANICS; MUSCLE WEAKNESS; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

DYSTROPHIN; EXONS; GENE THERAPY; HUMANS; MUSCULAR DYSTROPHIES;

ANIMALIA;

EID: 79956046546     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr105     Document Type: Article

References (126)

1. Campbell, K.P. (1995) Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell, 80, 675-679.
2. Kafri, T., Blomer, U., Peterson, D.A., Gage, F.H. and Verma, I.M. (1997) Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet., 17, 314-317.
3. Li, S., Kimura, E., Fall, B.M., Reyes, M., Angello, J.C., Welikson, R., Hauschka, S.D. and Chamberlain, J.S. (2005) Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther., 12, 1099-1108.
4. Beard, B.C., Keyser, K.A., Trobridge, G.D., Peterson, L.J., Miller, D.G., Jacobs, M., Kaul, R. and Kiem, H.P. (2007) Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum. Gene Ther., 18, 423-434.
5. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E. et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415-419.
6. MacKenzie, T.C., Kobinger, G.P., Louboutin, J.P., Radu, A., Javazon, E.H., Sena-Esteves, M., Wilson, J.M. and Flake, A.W. (2005) Transduction of satellite cells after prenatal intramuscular administration of lentiviral vectors. J. Gene Med., 7, 50-58.
7. Kimura, E., Li, S., Gregorevic, P., Fall, B.M. and Chamberlain, J.S. (2010) Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Mol. Ther., 18, 206-213.
8. Kobinger, G.P., Louboutin, J.P., Barton, E.R., Sweeney, H.L. and Wilson, J.M. (2003) Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum. Gene Ther., 14, 1441-1449.
9. Bachrach, E., Li, S., Perez, A.L., Schienda, J., Liadaki, K., Volinski, J., Flint, A., Chamberlain, J. and Kunkel, L.M. (2004) Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc. Natl Acad. Sci. USA, 101, 3581-3586.
10. Sampaolesi, M., Blot, S., D'Antona, G., Granger, N., Tonlorenzi, R., Innocenzi, A., Mognol, P., Thibaud, J.L., Galvez, B.G., Barthelemy, I. et al. (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature, 444, 574-579.
11. Larochelle, N., Teng, Q., Gilbert, R., Deol, J.R., Karpati, G., Holland, P.C. and Nalbantoglu, J. (2010) Modulation of coxsackie and adenovirus receptor expression for gene transfer to normal and dystrophic skeletal muscle. J. Gene Med., 12, 266-275.
12. Koppanati, B.M., Li, J., Xiao, X. and Clemens, P.R. (2009) Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders. Gene Ther., 16, 1130-1137.
13. Eghtesad, S., Zheng, H., Nakai, H., Epperly, M.W. and Clemens, P.R. (2010) Effects of irradiating adult mdx mice before full-length dystrophin cDNA transfer on host anti-dystrophin immunity. Gene Ther., 17, 1181-1190.
14. Jiang, Z., Schiedner, G., van Rooijen, N., Liu, C.C., Kochanek, S. and Clemens, P.R. (2004) Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade. Mol. Ther., 10, 688-696.
15. Jiang, Z., Schiedner, G., Gilchrist, S.C., Kochanek, S. and Clemens, P.R. (2004) CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle. Gene Ther., 11, 1453-1461.
16. Guibinga, G.H., Lochmuller, H., Massie, B., Nalbantoglu, J., Karpati, G. and Petrof, B.J. (1998) Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J. Virol., 72, 4601-4609.
17. Howell, J.M., Lochmuller, H., O'Hara, A., Fletcher, S., Kakulas, B.A., Massie, B., Nalbantoglu, J. and Karpati, G. (1998) High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum. Gene Ther., 9, 629-634.
18. Brunetti-Pierri, N., Palmer, D.J., Beaudet, A.L., Carey, K.D., Finegold, M. and Ng, P. (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther., 15, 35-46.
19. Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M. and Batshaw, M.L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80, 148-158.
20. Muzyczka, N. (1992) Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol., 158, 97-129.
21. Podsakoff, G., Wong, K.K. Jr and Chatterjee, S. (1994) Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J. Virol., 68, 5656-5666.
22. Herzog, R.W., Yang, E.Y., Couto, L.B., Hagstrom, J.N., Elwell, D., Fields, P.A., Burton, M., Bellinger, D.A., Read, M.S., Brinkhous, K.M. et al. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med., 5, 56-63.
23. Manno, C.S., Chew, A.J., Hutchison, S., Larson, P.J., Herzog, R.W., Arruda, V.R., Tai, S.J., Ragni, M.V., Thompson, A., Ozelo, M. et al. (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 101, 2963-2972.
24. Monahan, P.E., Samulski, R.J., Tazelaar, J., Xiao, X., Nichols, T.C., Bellinger, D.A., Read, M.S. and Walsh, C.E. (1998) Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther., 5, 40-49.
25. Rabinowitz, J.E. and Samulski, J. (1998) Adeno-associated virus expression systems for gene transfer. Curr. Opin. Biotechnol., 9, 470-475.
26. Gao, G., Vandenberghe, L.H., Alvira, M.R., Lu, Y., Calcedo, R., Zhou, X. and Wilson, J.M. (2004) Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol., 78, 6381-6388.
27. Zincarelli, C., Soltys, S., Rengo, G. and Rabinowitz, J.E. (2008) Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther., 16, 1073-1080.
28. Schultz, B.R. and Chamberlain, J.S. (2008) Recombinant adeno-associated virus transduction and integration. Mol. Ther., 16, 1189-1199.
29. Zincarelli, C., Soltys, S., Rengo, G., Koch, W.J. and Rabinowitz, J.E. (2010) Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin. Transl. Sci., 3, 81-89.
30. Gregorevic, P., Allen, J.M., Minami, E., Blankinship, M.J., Haraguchi, M., Meuse, L., Finn, E., Adams, M.E., Froehner, S.C., Murry, C.E. et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med., 12, 787-789.
31. Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller, D.G., Russell, D.W. and Chamberlain, J.S. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med., 10, 828-834.
32. Koppanati, B.M., Li, J., Reay, D.P., Wang, B., Daood, M., Zheng, H., Xiao, X., Watchko, J.F. and Clemens, P.R. (2010) Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene. Gene Ther., 17, 1355-1362.
33. Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J. and Xiao, X. (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol., 23, 321-328.
34. Pacak, C.A., Conlon, T., Mah, C.S. and Byrne, B.J. (2008) Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle. Genet. Vaccines Ther., 6, 14.
35. Mendell, J.R., Rodino-Klapac, L.R., Rosales, X.Q., Coley, B.D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B.J., Conlon, T. et al. (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol., 68, 629-638.
36. Mingozzi, F., Maus, M.V., Hui, D.J., Sabatino, D.E., Murphy, S.L., Rasko, J.E., Ragni, M.V., Manno, C.S., Sommer, J., Jiang, H. et al. (2007) CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med., 13, 419-422.
37. Mingozzi, F., Meulenberg, J.J., Hui, D.J., Basner-Tschakarjan, E., Hasbrouck, N.C., Edmonson, S.A., Hutnick, N.A., Betts, M.R., Kastelein, J.J., Stroes, E.S. et al. (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 114, 2077-2086.
38. Wang, Z., Storb, R., Lee, D., Kushmerick, M.J., Chu, B., Berger, C., Arnett, A., Allen, J., Chamberlain, J.S., Riddell, S.R. et al. (2010) Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol. Ther., 18, 617-624.
39. England, S.B., Nicholson, L.V., Johnson, M.A., Forrest, S.M., Love, D.R., Zubrzycka-Gaarn, E.E., Bulman, D.E., Harris, J.B. and Davies, K.E. (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature, 343, 180-182.
40. Matsumura, K., Burghes, A.H., Mora, M., Tome, F.M., Morandi, L., Cornello, F., Leturcq, F., Jeanpierre, M., Kaplan, J.C., Reinert, P. et al. (1994) Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. J. Clin. Invest., 93, 99-105.
41. Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps, S.F., Harper, H.A., Robinson, A.S., Engelhardt, J.F., Brooks, S.V. et al. (2002) Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med., 8, 253-261.
42. Wang, B., Li, J. and Xiao, X. (2000) Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl Acad. Sci. USA, 97, 13714-13719.
43. Sakamoto, M., Yuasa, K., Yoshimura, M., Yokota, T., Ikemoto, T., Suzuki, M., Dickson, G., Miyagoe-Suzuki, Y. and Takeda, S. (2002) Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. Biophys. Res. Commun., 293, 1265-1272.
44. Rafael, J.A., Cox, G.A., Corrado, K., Jung, D., Campbell, K.P. and Chamberlain, J.S. (1996) Forced expression of dystrophin deletion constructs reveals structure-function correlations. J. Cell Biol., 134, 93-102.
45. Gregorevic, P., Blankinship, M.J., Allen, J.M. and Chamberlain, J.S. (2008) Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol. Ther., 16, 657-664.
46. Wang, Z., Allen, J.M., Riddell, S.R., Gregorevic, P., Storb, R., Tapscott, S.J., Chamberlain, J.S. and Kuhr, C.S. (2007) Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum. Gene Ther., 18, 18-26.
47. Yuasa, K., Yoshimura, M., Urasawa, N., Ohshima, S., Howell, J.M., Nakamura, A., Hijikata, T., Miyagoe-Suzuki, Y. and Takeda, S. (2007) Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther., 14, 1249-1260.
48. Yue, Y., Ghosh, A., Long, C., Bostick, B., Smith, B.F., Kornegay, J.N. and Duan, D. (2008) A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther., 16, 1944-1952.
49. Mingozzi, F., Hasbrouck, N.C., Basner-Tschakarjan, E., Edmonson, S.A., Hui, D.J., Sabatino, D.E., Zhou, S., Wright, J.F., Jiang, H., Pierce, G.F. et al. (2007) Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 110, 2334-2341.
50. Mingozzi, F. and High, K.A. (2007) Immune responses to AAV in clinical trials. Curr. Gene Ther., 7, 316-324.
51. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B. et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12, 342-347.
52. Wang, Z., Kuhr, C.S., Allen, J.M., Blankinship, M., Gregorevic, P., Chamberlain, J.S., Tapscott, S.J. and Storb, R. (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther., 15, 1160-1166.
53. Jiang, H., Couto, L.B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J.A., Zhou, S., Scallan, C.D., Sommer, J., Vijay, S. et al. (2006) Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, 108, 3321-3328.
54. Mendell, J.R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G. et al. (2010) Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med., 363, 1429-1437.
55. Ferrer, A., Wells, K.E. and Wells, D.J. (2000) Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther., 7, 1439-1446.
56. Brantly, M.L., Chulay, J.D., Wang, L., Mueller, C., Humphries, M., Spencer, L.T., Rouhani, F., Conlon, T.J., Calcedo, R., Betts, M.R. et al. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl Acad. Sci. USA, 106, 16363-16368.
57. Yuasa, K., Sakamoto, M., Miyagoe-Suzuki, Y., Tanouchi, A., Yamamoto, H., Li, J., Chamberlain, J.S., Xiao, X. and Takeda, S. (2002) Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther., 9, 1576-1588.
58. Cordier, L., Gao, G.P., Hack, A.A., McNally, E.M., Wilson, J.M., Chirmule, N. and Sweeney, H.L. (2001) Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum. Gene Ther., 12, 205-215.
59. Hartigan-O'Connor, D., Kirk, C.J., Crawford, R., Mule, J.J. and Chamberlain, J.S. (2001) Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol. Ther., 4, 525-533.
60. Salva, M.Z., Himeda, C.L., Tai, P.W., Nishiuchi, E., Gregorevic, P., Allen, J.M., Finn, E.E., Nguyen, Q.G., Blankinship, M.J., Meuse, L. et al. (2007) Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther., 15, 320-329.
61. Wright, J.F., Wellman, J. and High, K.A. (2010) Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr. Gene Ther., 10, 341-349.
62. Foster, H., Sharp, P.S., Athanasopoulos, T., Trollet, C., Graham, I.R., Foster, K., Wells, D.J. and Dickson, G. (2008) Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther., 16, 1825-1832.
63. Gregorevic, P., Schultz, B.R., Allen, J.M., Halldorson, J.B., Blankinship, M.J., Meznarich, N.A., Kuhr, C.S., Doremus, C., Finn, E., Liggitt, D. et al. (2009) Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol. Ther., 17, 1427-1433.
64. Rodino-Klapac, L.R., Montgomery, C.L., Bremer, W.G., Shontz, K.M., Malik, V., Davis, N., Sprinkle, S., Campbell, K.J., Sahenk, Z., Clark, K.R. et al. (2010) Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther., 18, 109-117.
65. Bridges, C.R., Gopal, K., Holt, D.E., Yarnall, C., Cole, S., Anderson, R.B., Yin, X., Nelson, A., Kozyak, B.W., Wang, Z. et al.. (2005) Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J. Thorac. Cardiovasc. Surg., 130, 1364.
66. Su, L.T., Gopal, K., Wang, Z., Yin, X., Nelson, A., Kozyak, B.W., Burkman, J.M., Mitchell, M.A., Low, D.W., Bridges, C.R. et al. (2005) Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation, 112, 1780-1788.
67. Cho, W.K., Ebihara, S., Nalbantoglu, J., Gilbert, R., Massie, B., Holland, P., Karpati, G. and Petrof, B.J. (2000) Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. Hum. Gene Ther., 11, 701-714.
68. Budker, V., Zhang, G., Danko, I., Williams, P. and Wolff, J. (1998) The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther., 5, 272-276.
69. Greelish, J.P., Su, L.T., Lankford, E.B., Burkman, J.M., Chen, H., Konig, S.K., Mercier, I.M., Desjardins, P.R., Mitchell, M.A., Zheng, X.G. et al. (1999) Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat. Med., 5, 439-443.
70. Odom, G.L., Gregorevic, P., Allen, J.M., Finn, E. and Chamberlain, J.S. (2008) Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther., 16, 1539-1545.
71. Monaco, A.P., Bertelson, C.J., Liechti-Gallati, S., Moser, H. and Kunkel, L.M. (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics, 2, 90-95.
72. Sherratt, T.G., Vulliamy, T., Dubowitz, V., Sewry, C.A. and Strong, P.N. (1993) Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am. J. Hum. Genet., 53, 1007-1015.
73. Dunckley, M.G., Manoharan, M., Villiet, P., Eperon, I.C. and Dickson, G. (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet., 7, 1083-1090.
74. Mann, C.J., Honeyman, K., Cheng, A.J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J.E., Partridge, T.A. and Wilton, S.D. (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl Acad. Sci. USA, 98, 42-47.
75. Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S.A., Fletcher, S., Partridge, T.A. and Wilton, S.D. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med., 9, 1009-1014.
76. Pramono, Z.A., Takeshima, Y., Alimsardjono, H., Ishii, A., Takeda, S. and Matsuo, M. (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun., 226, 445-449.
77. Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D. and Wilton, S.D. (2006) Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med., 8, 207-216.
78. Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., Steinhaus, J.P., Moulton, H.M., Iversen, P.L. and Wilton, S.D. (2007) Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther., 15, 1587-1592.
79. Ivanova, G.D., Arzumanov, A., Abes, R., Yin, H., Wood, M.J., Lebleu, B. and Gait, M.J. (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res., 36, 6418-6428.
80. Yin, H., Lu, Q. and Wood, M. (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther., 16, 38-45.
81. Yokota, T., Lu, Q.L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S. and Hoffman, E. (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol., 65, 667-676.
82. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., Frankhuizen, W.S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J.T., Koop, K., van der Kooi, A.J., Goemans, N.M. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med., 357, 2677-2686.
83. Gebski, B.L., Mann, C.J., Fletcher, S. and Wilton, S.D. (2003) Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet., 12, 1801-1811.
84. Arechavala-Gomeza, V., Graham, I.R., Popplewell, L.J., Adams, A.M., Aartsma-Rus, A., Kinali, M., Morgan, J.E., van Deutekom, J.C., Wilton, S.D., Dickson, G. et al. (2007) Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther., 18, 798-810.
85. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P. et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol., 8, 918-928.
86. Goemans, N.M., Buyse, G., Tulinius, M., Verschuuren, J.J.G., de Kimpe, S.J. and van Deutekom, J.C.T. (2009) T.O.4 A phase I/IIa study on antisense compound PRO051 in patients with Duchenne muscular dystrophy. Neuromuscul. Disord., 19, 659-660.
87. Goemans, N., Tulinius, M., Buyse, G., Wilson, R., de Kimpe, S., van Deutekom, J. and Campion, G. (2010) O.15 24 week follow-up data from a phase I/IIa extension study of PRO051/GSK2402968 in subjects with Duchenne muscular dystrophy. Neuromuscul. Disord., 20, 639.
88. Shrewsbury, S.B., Cirak, S., Guglieri, M., Bushby, K. and Muntoni, F. (2010) O.16 Current progress and preliminary results with the systemic administration trial of AVI-4658, a novel phosphorodiamidate morpholino oligomer (PMO) skipping dystrophin exon 51 in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord., 20, 639-640.
89. Takeshima, Y., Nishio, H., Sakamoto, H., Nakamura, H. and Matsuo, M. (1995) Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J. Clin. Invest., 95, 515-520.
90. Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S.D., Partridge, T.A. and Lu, Q.L. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med., 12, 175-177.
91. Lu, Q.L., Rabinowitz, A., Chen, Y.C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G. and Partridge, T. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci. USA, 102, 198-203.
92. Yin, H., Moulton, H.M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P. and Wood, M.J. (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet., 17, 3909-3918.
93. Jearawiriyapaisarn, N., Moulton, H.M., Sazani, P., Kole, R. and Willis, M.S. (2010) Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc. Res., 85, 444-453.
94. Wu, B., Moulton, H.M., Iversen, P.L., Jiang, J., Li, J., Li, J., Spurney, C.F., Sali, A., Guerron, A.D., Nagaraju, K. et al. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl Acad. Sci. USA, 105, 14814-14819.
95. Wu, B., Lu, P., Benrashid, E., Malik, S., Ashar, J., Doran, T.J. and Lu, Q.L. (2010) Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther., 17, 132-140.
96. Moulton, H.M. and Moulton, J.D. (2010) Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta, 12, 2296-2303.
97. Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.J. and den Dunnen, J.T. (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat., 30, 293-299.
98. Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.C., Garcia, L. and Danos, O. (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science, 306, 1796-1799.
99. Denti, M.A., Rosa, A., D'Antona, G., Sthandier, O., De Angelis, F.G., Nicoletti, C., Allocca, M., Pansarasa, O., Parente, V., Musaro, A. et al. (2006) Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl Acad. Sci. USA, 103, 3758-3763.
100. De Angelis, F.G., Sthandier, O., Berarducci, B., Toso, S., Galluzzi, G., Ricci, E., Cossu, G. and Bozzoni, I. (2002) Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc. Natl Acad. Sci. USA, 99, 9456-9461.
101. Grimm, C., Stefanovic, B. and Schumperli, D. (1993) The low abundance of U7 snRNA is partly determined by its Sm binding site. EMBO J., 12, 1229-1238.
102. Benchaouir, R., Meregalli, M., Farini, A., D'Antona, G., Belicchi, M., Goyenvalle, A., Battistelli, M., Bresolin, N., Bottinelli, R., Garcia, L. et al. (2007) Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell, 1, 646-657.
103. Tinsley, J.M., Potter, A.C., Phelps, S.R., Fisher, R., Trickett, J.I. and Davies, K.E. (1996) Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature, 384, 349-353.
104. Gilbert, R., Nalbantoglu, J., Petrof, B.J., Ebihara, S., Guibinga, G.H., Tinsley, J.M., Kamen, A., Massie, B., Davies, K.E. and Karpati, G. (1999) Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum. Gene Ther., 10, 1299-1310.
105. Miura, P. and Jasmin, B.J. (2006) Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we? Trends Mol. Med., 12, 122-129.
106. Fisher, R., Tinsley, J.M., Phelps, S.R., Squire, S.E., Townsend, E.R., Martin, J.E. and Davies, K.E. (2001) Non-toxic ubiquitous overexpression of utrophin in the mdx mouse. Neuromuscul. Disord., 11, 713-721.
107. Gauthier-Rouviere, C. and Bonet-Kerrache, A. (2009) RhoA leads to up-regulation and relocalization of utrophin in muscle fibers. Biochem. Biophys. Res. Commun., 384, 322-328.
108. Khurana, T.S. and Davies, K.E. (2003) Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov., 2, 379-390.
109. Courdier-Fruh, I. and Briguet, A. (2006) Utrophin is a calpain substrate in muscle cells. Muscle Nerve, 33, 753-759.
110. Burkin, D.J., Wallace, G.Q., Nicol, K.J., Kaufman, D.J. and Kaufman, S.J. (2001) Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J. Cell Biol., 152, 1207-1218.
111. Rooney, J.E., Gurpur, P.B. and Burkin, D.J. (2009) Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc. Natl Acad. Sci. USA, 106, 7991-7996.
112. Kronqvist, P., Kawaguchi, N., Albrechtsen, R., Xu, X., Schroder, H.D., Moghadaszadeh, B., Nielsen, F.C., Frohlich, C., Engvall, E. and Wewer, U.M. (2002) ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice. Am. J. Pathol., 161, 1535-1540.
113. Amenta, A.R., Yilmaz, A., Bogdanovich, S., McKechnie, B.A., Abedi, M., Khurana, T.S. and Fallon, J.R. (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc. Natl Acad. Sci. USA, 108, 762-767.
114. Miura, P., Andrews, M., Holcik, M. and Jasmin, B.J. (2008) IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells. PLoS ONE, 3, e2309.
115. Lu, Y., Tian, C., Danialou, G., Gilbert, R., Petrof, B.J., Karpati, G. and Nalbantoglu, J. (2008) Targeting artificial transcription factors to the utrophin A promoter: effects on dystrophic pathology and muscle function. J. Biol. Chem., 283, 34720-34727.
116. Sonnemann, K.J., Heun-Johnson, H., Turner, A.J., Baltgalvis, K.A., Lowe, D.A. and Ervasti, J.M. (2009) Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med., 6, e1000083.
117. Welch, E.M., Barton, E.R., Zhuo, J., Tomizawa, Y., Friesen, W.J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C.R., Hwang, S. et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature, 447, 87-91.
118. Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E. and Sweeney, H.L. (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest., 104, 375-381.
119. Malik, V., Rodino-Klapac, L.R., Viollet, L., Wall, C., King, W., Al-Dahhak, R., Lewis, S., Shilling, C.J., Kota, J., Serrano-Munuera, C. et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol., 67, 771-780.
120. Finkel, R.S. (2010) Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J. Child Neurol., 25, 1158-1164.
121. Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M. and Kunkel, L.M. (1986) Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature, 323, 646-650.
122. Chung, W. and Campanelli, J.T. (1999) WW and EF hand domains of dystrophin-family proteins mediate dystroglycan binding. Mol. Cell Biol. Res. Commun., 2, 162-171.
123. Yang, B., Jung, D., Rafael, J.A., Chamberlain, J.S. and Campbell, K.P. (1995) Identification of alpha-syntrophin binding to syntrophin triplet, dystrophin, and utrophin. J. Biol. Chem., 270, 4975-4978.
124. Phelps, S.F., Hauser, M.A., Cole, N.M., Rafael, J.A., Hinkle, R.T., Faulkner, J.A. and Chamberlain, J.S. (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet., 4, 1251-1258.
125. Banks, G.B., Judge, L.M., Allen, J.M. and Chamberlain, J.S. (2010) The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet., 6, e1000958.
126. Beroud, C., Tuffery-Giraud, S., Matsuo, M., Hamroun, D., Humbertclaude, V., Monnier, N., Moizard, M.P., Voelckel, M.A., Calemard, L.M., Boisseau, P. et al. (2007) Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum. Mutat., 28, 196-202.